Cancer Therapy
Powered By You®
Syncromune® is at the forefront of developing personalized immunotherapies with the goal of helping patients with advanced cancer. Our therapy is designed to activate and empower your immune system to attack cancer.
A new approach
designed to deliver
better patient outcomes
The SYNC-T Therapy is an entirely new approach to treating metastatic solid tumor cancers. It is an in situ (within the body) personalized therapy that combines partial tumor oncolysis and a multi-target biologic drug with a goal of combating cancer in several different ways. This diverse approach is designed to empower your immune system to recognize and attack cancer throughout the body.
A new approach designed to deliver better patient outcomes
The SYNC-T Therapy is an entirely new approach to treating metastatic solid tumor cancers. It is an in situ (within the body) personalized therapy that combines partial tumor oncolysis and a multi-target biologic drug with a goal of combating cancer in several different ways. This diverse approach is designed to empower your immune system to recognize and attack cancer throughout the body.
Patient Resources
The following are additional resources to learn more about immunotherapy, SYNC-T's initial indications, metastatic non-small cell lung cancer, metastatic breast cancer, and metastatic castrate-resistant prostate cancer
Investigational Clinical Trials for Solid Tumors
We’re committed to our mission of developing new therapies that may help improve the lives of patients with cancer. Our clinical trials for solid tumor cancers study combination investigational drugs and medical devices. Some of these trials are investigator-initiated by external researchers to assess the potential of these therapies in treating advanced cancer. We collaborate with these investigators to contribute to the advancement of cancer treatment.
STATUS
TRIAL NAME
TRIAL REFERENCE NUMBER
RECRUITING
Phase 1 Investigator Initiated Trial of SYNC-T SV-101 Immunotherapy for Patients With Advanced / Metastatic Breast Cancer
STATUS
TRIAL NAME
TRIAL REFERENCE NUMBER
ENROLLMENT CLOSED
Phase 1 Investigator Initiated Trial of SYNC-T SV-101 Immunotherapy for Patients With Advanced / Metastatic Non-Small Cell Lung Cancer
STATUS
TRIAL NAME
TRIAL REFERENCE NUMBER
ENROLLMENT CLOSED
Phase 1 Investigator Initiated Trial of SYNC-T SV-102 Immunotherapy for Advanced/Metastatic Castrate-Resistant Prostate Cancer
Locations
Hospital Diomed
Mexico City, MX
Condition
Metastatic Castrate-Resistant Prostate Cancer
STATUS
TRIAL NAME
TRIAL REFERENCE NUMBER
NOT YET RECRUITING
LEGION-100: A Phase 1b Open-Label, Dose-Escalation Study of SYNC-T Therapy SV-102 in Patients Diagnosed With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Locations
United States
Condition
Metastatic Castrate-Resistant Prostate Cancer
Expanded Access to Investigational Therapies
Syncromune is an oncology-focused biopharmaceutical company committed to developing therapies that may improve the lives of cancer patients. Our focus centers around conducting clinical research that evaluates the safety and effectiveness of new therapies for patients with solid tumor cancers. Our clinical trial programs are the primary way to get access to a Syncromune investigational therapy. These clinical trials provide the most effective way to assess how our investigational therapies may treat cancer, and are used to support regulatory approval.
At this time, Syncromune does not provide access to investigational therapies outside of clinical trials or prior to regulatory approval. You and your health care provider may learn more about our clinical trials by going to the clinical trials section of our website, or visiting ClinicalTrials.gov and searching for Syncromune.
If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to trials@syncromune.com. Syncromune will acknowledge your request as soon as possible, typically within 3 days of receipt.
If applicable, this website will be updated with hyperlinks to the relevant expanded access information on ClinicalTrials.gov . Syncromune reserves the right to revise this expanded access policy at any time.
Pursuant to the 21st Century Cures Act, the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual.
Disclaimers: The content on this website is intended for healthcare professionals. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.
